TNXP Tonix Pharmaceuticals Holding Corp.
Price Chart
Executive Summary
Tonix Pharmaceuticals announced upcoming presentations at the AACR Annual Meeting 2026 on its preclinical immuno-oncology programs, including data on TNX-1700, an investigational fusion protein for gastric and colorectal cancer. The presentations highlight preclinical research but do not include clinical trial results or regulatory approvals. The company remains in the pre-IND stage for these candidates.
Actionable Insight
Traders should monitor for follow-up announcements after the AACR presentations, particularly if data support IND filing for TNX-1700. However, no material near-term catalysts are expected given the early stage of development.
Key Facts
- Tonix will present one oral and two poster presentations at AACR 2026 on its preclinical immuno-oncology programs.
- TNX-1700, a TFF2-albumin fusion protein, is in preclinical development for gastric and colorectal cancer and remains in pre-IND stages.
- No clinical data, regulatory decisions, or financial results were disclosed.
- Presentations focus on mechanism of action, in vitro characterization of anti-BTLA antibodies, and pharmacokinetics in animal models.
- TNX-1700 is in-licensed from Columbia University; collaboration includes scientific co-authorship.
Financial Impact
No immediate financial impact; preclinical data unlikely to affect near-term revenue or expenses
Risk Factors
- Preclinical results may not translate to clinical efficacy.
- No guarantee that TNX-1700 will advance to clinical trials or receive regulatory approval.
- Limited market interest in early-stage immuno-oncology assets without human data.
Market Snapshot
Documents Analyzed
This report is based on 1 press release from GlobeNewswire.
| Document | Accession Number |
|---|---|
| PRESS-RELEASE Data (Synthetic) | press-3257693 |
Filters
| Type | Now | ||||
|---|---|---|---|---|---|
|
Jun 9, 2026
today
|
Insider Cluster
| $11.71 awaiting T+5 | awaiting T+5 | — | $11.46 (−2.13%) |
|
Jun 8, 2026
1d ago
|
8-K
| $11.05 awaiting T+5 | awaiting T+5 | — | $11.46 (+3.71%) |
|
May 15, 2026
25d ago
|
8-K
| $15.74 $12.77 | ▼ −18.87% | ▼ −19.83% | $11.46 (−27.19%) |
|
May 14, 2026
26d ago
|
Press Release
| $14.09 $14.00 | ▼ −0.64% | ▲ +0.08% | $11.46 (−18.67%) |
|
May 11, 2026
29d ago
|
8-K
| $13.28 $14.26 | ▼ −7.38% | ▼ −7.30% | $11.46 (+13.70%) |
|
Apr 29, 2026
5w ago
|
8-K
| $12.40 $13.50 | ▲ +8.87% | ▲ +5.76% | $11.46 (−7.58%) |
|
Apr 23, 2026
6w ago
|
8-K
| $12.49 $12.40 | ▼ −0.72% | ▼ −2.20% | $11.46 (−8.25%) |
|
Apr 15, 2026
7w ago
|
Press Release
| $14.34 $13.11 | ▼ −8.58% | ▼ −10.22% | $11.46 (−20.08%) |
|
Mar 26, 2026
10w ago
|
Press Release
| $13.75 $13.90 | ▲ +1.09% | ▼ −0.54% | $11.46 (−16.65%) |
|
Mar 23, 2026
11w ago
|
Press Release
| $15.34 $13.75 | ▼ −10.37% | ▼ −9.94% | $11.46 (−25.29%) |
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Try SecBot Free Coming soon: SecBot Pro with alerts, watchlists, and API access